Minireviews
Copyright ©The Author(s) 2019.
World J Gastroenterol. Apr 21, 2019; 25(15): 1817-1827
Published online Apr 21, 2019. doi: 10.3748/wjg.v25.i15.1817
Table 2 Conditions to consider when determining therapeutic options
ChangeRisk
Decreased cardiac functionUse of endoscopic therapy
Use of beta-blockers
Increase in blood pressure caused by molecular targeted agent
Decreased renal functionUse of contrast medium
Use of interventional radiology for hepatocellular carcinoma
Rapid change in circulation dynamics
Decreased respiratory functionAspiration pneumonia
Ease of electrolyte abnormalitiesHigher risk of using diuretics
DementiaDifficulty in differentiating hepatic encephalopathy from dementia and cerebrovascular diseases
Aging of gut microbiotaHepatic encephalopathy
Loss of bone densityOsteoporosis
Risk of fall-related injury
Loss of muscle volumeSarcopenia
Risk of fall-related injury
Dry skinPruritus
Hand–foot syndrome caused by molecular targeted agent